A.D.A.M. and the Icahn School of Medicine at Mount Sinai Announce Collaboration to Advance Bone Implant Technology and Healthcare Innovation

Collaboration

Advanced Development of Additive Manufacturing (A.D.A.M.), a provider of 3D printing systems for customized bone implants, and the Icahn School of Medicine at Mount Sinai, in New York, NY, a renowned educational and health institution, have established a collaboration, which aims to enhance healthcare by innovating in bone implant delivery and soft tissue medical device development.

Agreement

The agreement involves A.D.A.M. and Mount Sinai BioDesign, Icahn Mount Sinai’s medical device innovation incubator, combining their technological and expert capabilities to improve patient care in the field of bone implant delivery.

Denys Gurak, CEO and Founder of A.D.A.M.

“Our collaboration with Icahn Mount Sinai leverages our advanced medical device production system and Icahn Mount Sinai’s expertise to improve patient care in healthcare.”

Benjamin Rapoport, MD, PhD, Assistant Professor of Neurosurgery and Scientific Director of Mount Sinai BioDesign

“Our collaboration with A.D.A.M. unites our medical device innovation skills with their 3D printing technology, reflecting our dedication to solving healthcare challenges through joint efforts.”

The collaboration will conduct research and development in 3D printed bone tissues using A.D.A.M.’s technology and will explore soft tissue printing through the new “Soft Tissues Working Group.”

An important aspect of this relationship will be work conducted at A.D.A.M. ‘s pilot facility at the Masovian Regional Hospital in Siedlce, Poland.

A.D.A.M. Inc. was a participant of the 2022 Spring Cohort of Mount Sinai Innovation Partners’ Elementa Labs incubator program and Icahn Mount Sinai has a financial interest in the company.

SourceA.D.A.M.

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."